BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study.

已完结 10 由 flower 发布于 2026/6/3 12:06:17

DOI:10.1016/S1470-2045(24)00159-1
作者：Yuxiang Ma, Yan Huang, Yuanyuan Zhao, Shen Zhao, Jinhui Xue, Yunpeng Yang, Wenfeng Fang, Ye Guo, Yaqian Han, Kunyu Yang, Yongsheng Li, Jun Yang,&
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Antibody-drug conjugates have promising clinical activity in the treatment of solid tumours. BL-B01D1 is a first-in-class EGFR-HER3 bispecific antibody-drug conjugate. We aimed t

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Bone Destruction-Chemotactic Osteoprogenitor Cells Deliver Liposome Nanomedicines for the Treatment of Osteosarcoma and Osteoporosis